Back to Top

NSCLC

Osimertinib granted FDA BTD for adjuvant treatment of resectable, EGFRmut NSCLC

Interim analysis of the phase 3 ADAURA study showed a significant improvement in DFS, and study was unblinded early in April 2020 (AZ press release)

Pages

Subscribe to RSS - NSCLC